{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:17:45Z","timestamp":1788200265680,"version":"build-2803163510"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ctrv.2024.102716","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:39:14Z","timestamp":1710131954000},"page":"102716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-4060","authenticated-orcid":false,"given":"A.","family":"Kyriazoglou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pagkali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kotsantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Economopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kyrkasiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moutafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gavrielatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boulouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pantazopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Giannakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Digklia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Psyrri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102716_b0005","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) program. Cancer stat facts: soft tissue including heart cancer. 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/soft.html (accessed on Feb 12, 2022)."},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1053\/adpa.2000.8133","article-title":"Liposarcoma: new entities and evolving concepts","volume":"4","author":"Dei Tos","year":"2000","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102716_b0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/his.14548","article-title":"What's new in adipocytic neoplasia?","volume":"80","author":"Thway","year":"2022","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102716_b0020","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/cncr.21933","article-title":"Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas","volume":"106","author":"Fabre-Guillevin","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102716_b0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00000478-199703000-00002","article-title":"Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation","volume":"21","author":"Henricks","year":"1997","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102716_b0030","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/01.pas.0000170343.09562.39","article-title":"MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data","volume":"29","author":"Binh","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102716_b0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"Sleijfer","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102716_b0040","unstructured":"PDQ Adult Treatment Editorial Board. Soft Tissue Sarcoma Treatment (PDQ\u00ae): Health Professional Version. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); March 3, 2023."},{"issue":"9325","key":"10.1016\/j.ctrv.2024.102716_b0045","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O'Sullivan","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102716_b0050","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Jan 23, 2020. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf. Version 5.2019 (accessed on Feb 12, 2022)."},{"issue":"7","key":"10.1016\/j.ctrv.2024.102716_b0055","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ejso.2016.02.004","article-title":"Combining limb-sparing surgery with radiation therapy in high-grade soft tissue sarcoma of extremities - Is it effective?","volume":"42","author":"M\u00fcller","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102716_b0060","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0065","doi-asserted-by":"crossref","unstructured":"Callegaro D, Raut CP, Ajayi T, et al. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 trial (STRASS) versus off-trial (STREXIT) Results [published online ahead of print, 2022 Jul 14]. Ann Surg. 2022;10.1097\/SLA.0000000000005492.","DOI":"10.1097\/SLA.0000000000005492"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0070","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.02.5577","article-title":"Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514","volume":"24","author":"Kraybill","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102716_b0075","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdh431","article-title":"Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma","volume":"15","author":"Grobmyer","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0080","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0360-3016(03)00186-X","article-title":"Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas","volume":"56","author":"DeLaney","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF02573888","article-title":"Preoperative chemoradiation treatment strategies for localized sarcoma","volume":"9","author":"Pisters","year":"2002","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"#cr-split#-10.1016\/j.ctrv.2024.102716_b0095.1","doi-asserted-by":"crossref","unstructured":"Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial [published correction appears in J Clin Oncol. 2005 Aug 1","DOI":"10.1200\/JCO.2005.01.180"},{"key":"#cr-split#-10.1016\/j.ctrv.2024.102716_b0095.2","doi-asserted-by":"crossref","unstructured":"23(22): 5276]. J Clin Oncol. 2005;23(3):576-584.","DOI":"10.1200\/JCO.2005.05.943"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102716_b0100","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","article-title":"Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy","volume":"22","author":"Garcia-Carbonero","year":"2004","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102716_b0105","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102716_b0110","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2004.05.210","article-title":"Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients","volume":"22","author":"Yovine","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0115","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.11563","article-title":"Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma","volume":"98","author":"Laverdiere","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102716_b0120","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2002.20.5.1329","article-title":"Increasing single epirubicin doses in advanced soft tissue sarcomas","volume":"20","author":"Lopez","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102716_b0125","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","article-title":"Randomised comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas","volume":"11","author":"Edmonson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102716_b0130","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","article-title":"An intergroup phase III randomised study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas","volume":"11","author":"Antman","year":"1993","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102716_b0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.1989.7.9.1208","article-title":"Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy","volume":"7","author":"Elias","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0140","doi-asserted-by":"crossref","unstructured":"Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial [published correction appears in Lancet. 2016 Jul 30;388(10043):464]. Lancet. 2016;388(10043):488-497.","DOI":"10.1016\/S0140-6736(16)30587-6"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102716_b0145","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0155","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdr485","article-title":"Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival","volume":"23","author":"Italiano","year":"2012","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102716_b0160","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1080\/14656566.2016.1229304","article-title":"Efficacy of trabectedin for the treatment of liposarcoma","volume":"17","author":"Zijoo","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102716_b0165","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10637-008-9217-1","article-title":"Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma","volume":"27","author":"Fayette","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2024.102716_b0170","doi-asserted-by":"crossref","unstructured":"Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial [published correction appears in Lancet Oncol. 2018 Feb;19(2):e78]. Lancet Oncol. 2017;18(8):1089-1103.","DOI":"10.1016\/S1470-2045(17)30381-9"},{"issue":"32","key":"10.1016\/j.ctrv.2024.102716_b0175","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"PICASSO III: A phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma","volume":"34","author":"Ryan","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102716_b0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2045-3329-4-16","article-title":"High-dose continuous-infusion ifosfamide in advanced well-differentiated\/dedifferentiated liposarcoma","volume":"4","author":"Sanfilippo","year":"2014","journal-title":"Clin Sarcoma Res"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102716_b0185","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","article-title":"Randomised phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study","volume":"29","author":"Garc\u00eda-Del-Muro","year":"2011","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ctrv.2024.102716_b0190","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomised phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0195","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/annonc\/mds659","article-title":"Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study","volume":"24","author":"Samuels","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102716_b0200","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomised multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12 Suppl","key":"10.1016\/j.ctrv.2024.102716_b0205","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon.13.207","article-title":"Trabectedin mechanism of action: what's new?","volume":"9","author":"D'Incalci","year":"2013","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102716_b0210","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(15)70031-8","article-title":"Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial","volume":"16","author":"Le Cesne","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102716_b0215","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdy253","article-title":"Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomised controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"29","author":"Jones","year":"2018","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0220","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejca.2015.01.006","article-title":"Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group","volume":"51","author":"Le Cesne","year":"2015","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102716_b0225","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.32117","article-title":"Overall survival and histology-specific subgroup analyses from a phase 3, randomised controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102716_b0230","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/cancers13051053","article-title":"Trabectedin for patients with advanced soft tissue sarcoma: a non-interventional, retrospective, multicenter study of the Italian Sarcoma Group","volume":"13","author":"Palmerini","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7\u20138","key":"10.1016\/j.ctrv.2024.102716_b0235","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000500608","article-title":"Retrospective analysis of patients with advanced liposarcoma in a tertiary referral center","volume":"42","author":"Langmans","year":"2019","journal-title":"Oncol Res Treat"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102716_b0240","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1007\/s12325-017-0561-4","article-title":"Systemic therapy for soft tissue sarcoma: proposals for the optimal use of pazopanib, trabectedin, and eribulin","volume":"34","author":"Kawai","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jjco\/hyw175","article-title":"Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma","volume":"47","author":"Kawai","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0250","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes [published correction appears in Lancet Oncol. 2015 Sep;16(9):e427]. Lancet Oncol. 2011;12(11):1045-1052.","DOI":"10.1016\/S1470-2045(11)70230-3"},{"issue":"10028","key":"10.1016\/j.ctrv.2024.102716_b0255","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102716_b0260","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-16-2422","article-title":"FDA approval summary: eribulin for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen","volume":"23","author":"Osgood","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102716_b0265","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/genes13030466","article-title":"Recent development of prodrugs of gemcitabine","volume":"13","author":"Pandit","year":"2022","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0270","first-page":"106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0275","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0959-8049(01)00408-7","article-title":"Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"38","author":"Svanc\u00e1rov\u00e1","year":"2002","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102716_b0280","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/cncr.11290","article-title":"Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group","volume":"97","author":"Okuno","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0285","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00000421-199612000-00008","article-title":"Phase II study of docetaxel in advanced soft tissue sarcomas","volume":"19","author":"Edmonson","year":"1996","journal-title":"Am J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102716_b0290","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1012272007146","article-title":"Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial","volume":"12","author":"K\u00f6stler","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0295","doi-asserted-by":"crossref","unstructured":"Maki RG, Wathen JK, Patel SR, et al. Randomised phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected] [published correction appears in J Clin Oncol. 2007 Aug 20;25(24):3790]. J Clin Oncol. 2007;25(19):2755-2763.","DOI":"10.1200\/JCO.2006.10.4117"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102716_b0300","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0305","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10637-016-0410-3","article-title":"Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors","volume":"35","author":"Paz-Ares","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2024.102716_b0310","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2019.10.021","article-title":"A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and\/or unresectable sarcomas","volume":"126","author":"Cote","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102716_b0315","first-page":"219","article-title":"Effects of lipid based Multiple Micronutrients Supplement on the birth outcome of underweight pre-eclamptic women: A randomised clinical trial","volume":"38","author":"Mohammad","year":"2022","journal-title":"Pak J Med Sci"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0320","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"issue":"19","key":"10.1016\/j.ctrv.2024.102716_b0325","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9829","key":"10.1016\/j.ctrv.2024.102716_b0330","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2024.102716_b0335","doi-asserted-by":"crossref","unstructured":"Karch A, Koch A, Gr\u00fcnwald V. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomised controlled trial. Trials. 2016;17(1):312. Published 2016 Jul 7.","DOI":"10.1186\/s13063-016-1434-x"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102716_b0340","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cncr.30926","article-title":"Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"123","author":"Samuels","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2024.102716_b0345","doi-asserted-by":"crossref","unstructured":"Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105. Published 2016 Oct 4.","DOI":"10.1186\/s13045-016-0332-8"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102716_b0350","article-title":"Anlotinib: A novel targeted drug for bone and soft tissue sarcoma","volume":"20","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2024.102716_b0355","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0360","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/CAD.0000000000001023","article-title":"Efficacy and safety of anlotinib in patients with unresectable or metastatic well-differentiated\/dedifferentiated liposarcoma: a single-center retrospective study","volume":"32","author":"Li","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"5594","key":"10.1016\/j.ctrv.2024.102716_b0365","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"issue":"32","key":"10.1016\/j.ctrv.2024.102716_b0370","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0375","doi-asserted-by":"crossref","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia [published correction appears in N Engl J Med. 2016 Mar 10;374(10):998]. N Engl J Med. 2011;365(8):725-733.","DOI":"10.1056\/NEJMoa1103849"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102716_b0380","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102716_b0385","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102716_b0390","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CJI.0000000000000183","article-title":"First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing NY-ESO-1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma patient","volume":"40","author":"Pollack","year":"2017","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102716_b0395","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.pathol.2017.05.003","article-title":"PD-1 and PD-L1 expression in bone and soft tissue sarcomas","volume":"49","author":"Torabi","year":"2017","journal-title":"Pathology"},{"key":"10.1016\/j.ctrv.2024.102716_b0400","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/547460","article-title":"Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma","volume":"2015","author":"Tseng","year":"2015","journal-title":"Sarcoma"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102716_b0405","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12885-016-2451-6","article-title":"Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma","volume":"8","author":"Kim","year":"2016","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102716_b0410","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12032-016-0807-z","article-title":"Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas","volume":"33","author":"Paydas","year":"2016","journal-title":"Med Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2024.102716_b0415","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102716_b0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"issue":"Pt 2","key":"10.1016\/j.ctrv.2024.102716_b0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcancer.2017.10.001","article-title":"Emerging targets in cancer immunotherapy","volume":"52","author":"Burugu","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102716_b0430","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102716_b0435","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/s41379-019-0312-y","article-title":"Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas","volume":"32","author":"Dancsok","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2024.102716_b0440","unstructured":"Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial [published correction appears in Lancet Oncol. 2017 Dec;18(12):e711] [published correction appears in Lancet Oncol. 2018 Jan;19(1):e8]. Lancet Oncol. 2017;18(11):1493-1501."},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-020-0705-7","article-title":"Dedifferentiated liposarcoma: systemic therapy options","volume":"21","author":"Gahvari","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0450","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/13543784.2019.1607291","article-title":"Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"28","author":"Chamberlain","year":"2019","journal-title":"Expert Opin Invest Drugs"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102716_b0455","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0460","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0465","doi-asserted-by":"crossref","first-page":"e001561","DOI":"10.1136\/jitc-2020-001561","article-title":"Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial","volume":"8","author":"Martin-Broto","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102716_b0470","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1097\/PAS.0b013e3180581fff","article-title":"Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR","volume":"31","author":"Sirvent","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0475","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20835","article-title":"Evaluation of well-differentiated\/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization","volume":"50","author":"Tap","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102716_b0480","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/0008-5472.CAN-07-0584","article-title":"Gene expression profiling of liposarcoma identifies distinct biological types\/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma","volume":"67","author":"Singer","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102716_b0485","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2024.102716_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103029","article-title":"Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review","volume":"153","author":"Assi","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"issue":"16","key":"10.1016\/j.ctrv.2024.102716_b0495","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102716_b0500","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaoncol.2016.0264","article-title":"Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial","volume":"2","author":"Dickson","year":"2016","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102716_b0505","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/ijc.33956","article-title":"Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center","volume":"150","author":"Nassif","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2024.102716_b0510","doi-asserted-by":"crossref","unstructured":"Marretta AL, Di Lorenzo G, Ribera D, et al. Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors. Pharmaceutics. 2021;13(9):1522. Published 2021 Sep 20.","DOI":"10.3390\/pharmaceutics13091522"},{"issue":"22","key":"10.1016\/j.ctrv.2024.102716_b0515","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomised, double-blind, placebo-controlled trial","volume":"40","author":"Gounder","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0520","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s12094-019-02158-z","article-title":"Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification","volume":"22","author":"Cornillie","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0525","doi-asserted-by":"crossref","unstructured":"Patrick Sch\u00f6ffski, Mehdi Lahmar, Anthony Lucarelli, Robert G Maki. Brightline-1: phase II\/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Future Oncol. 2023 Mar;19(9):621-629. doi: 10.2217\/fon-2022-1291, Epub 2023 Mar 29.","DOI":"10.2217\/fon-2022-1291"},{"key":"10.1016\/j.ctrv.2024.102716_b0530","unstructured":"Gr\u00fcnewald TG, Alonso M, Avnet S, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020 Nov 6;12(11):e11131. doi: 10.15252\/emmm.201911131. Epub 2020 Oct 13. PMID: 33047515; PMCID: PMC7645378."},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0535","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/CCO.0000000000000851","article-title":"First and further-line multidisciplinary treatment of retroperitoneal sarcomas","volume":"34","author":"D'Ambrosio","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102716_b0540","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11864-023-01057-4","article-title":"Myxoid liposarcomas: systemic treatment options","volume":"24","author":"Nassif","year":"2023","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102716_b0545","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fonc.2017.00292","article-title":"Systemic therapy in metastatic or unresectable well-differentiated\/dedifferentiated liposarcoma","volume":"30","author":"McGovern","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0550","doi-asserted-by":"crossref","unstructured":"Spalato-Ceruso M, Bouteiller F, Guegan JP, et al. Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study. J Hematol Oncol. 2022;15(1):157. Published 2022 Oct 27.","DOI":"10.1186\/s13045-022-01377-2"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102716_b0555","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","article-title":"Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort","volume":"28","author":"Italiano","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2024.102716_b0560","article-title":"Brightline-1: phase II\/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS [published online ahead of print, 2023 Mar 29]","author":"Sch\u00f6ffski","year":"2023","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102716_b0565","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejso.2022.08.024","article-title":"Dedifferentiated liposarcoma in the extremity and trunk wall: A multi-institutional study of 132 cases by the Japanese Musculoskeletal Oncology Group (JMOG)","volume":"49","author":"Morii","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ctrv.2024.102716_b0570","doi-asserted-by":"crossref","unstructured":"Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial [published correction appears in Lancet Oncol. 2017 Jun;18(6):e301]. Lancet Oncol. 2017;18(6):812-822.","DOI":"10.1016\/S1470-2045(17)30334-0"},{"key":"10.1016\/j.ctrv.2024.102716_b0575","doi-asserted-by":"crossref","unstructured":"Livingston JA, Bugano D, Barbo A, et al. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep. 2017;7(1):11836. Published 2017 Sep 19.","DOI":"10.1038\/s41598-017-12132-w"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102716_b0580","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s12885-022-09527-y","article-title":"Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study","volume":"22","author":"Kawai","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102716_b0585","unstructured":"Kawai A, Araki N, Naito Y, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:31:18Z","timestamp":1759656678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":118,"alternative-id":["S0305737224000434"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102716","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102716"}}